The 15 references in paper A. Esayan M., I. Kayukov G., A. Nimgirova N., E. Zuyeva E., T. Denisova V., O. Galkina V., А. Есаян М., И. Каюков Г., А. Нимгирова Н., Е. Зуева Е., Т. Денисова В., О. Галкина В. (2012) “ФАКТОР РОСТА ФИБРОБЛАСТОВ 23-го ТИПА У РЕЦИПИЕНТОВ ПОЧЕЧНОГО АЛЛОТРАНСПЛАНТАТА // FIBROBLAST GROWTH FACTOR 23 IN RENAL ALLOGRAFT RECEPIENTS” / spz:neicon:nefr:y:2012:i:4:p:50-54

1
Wolfe RA, Ashby VB, Milford EL. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730
(check this in PDF content)
2
Pascual M, Theruvath T, Kawai T. et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580–590
(check this in PDF content)
3
Howard RJ, Patton PR, Reed AI. Et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923–1928,
(check this in PDF content)
4
Mirza MA, Hansen T, Johansson L. et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009; 24: 3125–3131
(check this in PDF content)
5
Mirza MA, Larsson A, Melhus H. et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546–551
(check this in PDF content)
6
Levi M. Post-transplant hypophosphatemia. Kidney Int 2001; 59:2377– 2387
(check this in PDF content)
7
Heine GH, Seiler S, Fliser D. FGF-23: The Rise of a Novel Cardiovascular Risk Marker in CKD. Nephrol Dial Transplant 2012;27(8):3072-3081
(check this in PDF content)
8
Gutierrez O, Isakova T, Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205–2215
(check this in PDF content)
9
Evenepoel P, Meijers BKI, de Jonge H. et al. Recovery of Hyperphosphatoninism and Renal Phosphorus Wasting One Year after Successful Renal Transplantation. CJASN 2008; 3 (6) 1829-1836
(check this in PDF content)
10
Howard RJ, Patton PR, Reed AI. et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923–1928.
(check this in PDF content)
11
Levey AS, Greene T, Beck GJ. et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 1999; 10: 2426-2439
(check this in PDF content)
12
Sanchez CP, Salusky IB, Kuizon BD. et al. Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 1998; 53: 1358–1364
(check this in PDF content)
13
Kidney Disease: Improving Global Outcome (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKDMBD). Kidney Int 2009; 113 Suppl: S1–S130
(check this in PDF content)
14
Ball AM, Gillen DL, Sherrard D et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288: 3014–3018
(check this in PDF content)
15
Ramezani M, Einollahi B, Asl MA. et al. Calcium and phosphorus metabolism disturbances after renal transplantation. Transplant Proc 2007; 39:1033–1035 Поступила в редакцию 24.09.2012 г. Принята в печать 11.10.2012 г.
(check this in PDF content)